ChartMillAugust 6, 2026 at 8:02 PM NY28 days ago
CytomX Therapeutics (NASDAQ:CTMX) Shares Plunge After Q2 Revenue and EPS Miss Estimates
Cytomx (CTMX) shares fell ~30% after Q2 revenue and EPS missed estimates. Lead program Varseta-M Phase 1 data expected by end of 2026.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — ChartMill
Companies in This Story
Related Stories
Exploring the top movers within the S&P500 index during today's session.
ChartMill43 minutes ago
Sector Update: Financial
Yahoo2 hours ago
Will Fiserv’s (FISV) Cut 2026 Outlook and Margin Pressures Change Its Transformation Narrative?
Yahoo2 hours ago
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill2 hours ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill3 hours ago